Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
14
08
2022
accepted:
17
01
2023
revised:
05
01
2023
medline:
28
4
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking. Patient performance status, tumour burden (determined by the presence or absence of liver metastases), plasma protein biomarkers (CA19-9, albumin, C-reactive protein and neutrophils) and circulating tumour DNA (ctDNA) were assessed in 146 patients with metastatic PDAC prior to starting either concomitant or sequential nab-paclitaxel + gemcitabine chemotherapy in the SIEGE randomised prospective clinical trial, as well as during the first 8 weeks of treatment. Correlations were made with objective response, death within 1 year and overall survival (OS). Initial poor patient performance status, presence of liver metastases and detectable Readily measurable patient variables can aid the prediction of outcomes from combination chemotherapy used to treat metastatic PDAC. The role of ISRCTN71070888; ClinialTrials.gov (NCT03529175).
Sections du résumé
BACKGROUND
Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking.
METHODS
Patient performance status, tumour burden (determined by the presence or absence of liver metastases), plasma protein biomarkers (CA19-9, albumin, C-reactive protein and neutrophils) and circulating tumour DNA (ctDNA) were assessed in 146 patients with metastatic PDAC prior to starting either concomitant or sequential nab-paclitaxel + gemcitabine chemotherapy in the SIEGE randomised prospective clinical trial, as well as during the first 8 weeks of treatment. Correlations were made with objective response, death within 1 year and overall survival (OS).
RESULTS
Initial poor patient performance status, presence of liver metastases and detectable
CONCLUSIONS
Readily measurable patient variables can aid the prediction of outcomes from combination chemotherapy used to treat metastatic PDAC. The role of
CLINICAL TRIAL REGISTRATION
ISRCTN71070888; ClinialTrials.gov (NCT03529175).
Identifiants
pubmed: 36813867
doi: 10.1038/s41416-023-02170-9
pii: 10.1038/s41416-023-02170-9
pmc: PMC10133256
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Paclitaxel
P88XT4IS4D
CA-19-9 Antigen
0
Albumins
0
Banques de données
ClinicalTrials.gov
['NCT03529175']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1672-1680Informations de copyright
© 2023. The Author(s).
Références
Curr Med Res Opin. 2018 May;34(5):857-863
pubmed: 29161926
Oncologist. 2018 May;23(5):566-572
pubmed: 29371474
Clin Cancer Res. 2013 Oct 1;19(19):5456-64
pubmed: 23938289
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
Sci Rep. 2021 Jan 12;11(1):781
pubmed: 33437015
Ann Oncol. 2016 Apr;27(4):654-60
pubmed: 26802160
Cancers (Basel). 2019 Jun 19;11(6):
pubmed: 31248203
Crit Rev Oncol Hematol. 2018 Dec;132:130-137
pubmed: 30447918
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Lancet Oncol. 2018 Mar;19(3):e151-e160
pubmed: 29508762
World J Gastroenterol. 2017 Mar 14;23(10):1872-1880
pubmed: 28348494
Aging (Albany NY). 2021 Jan 6;13(1):1410-1421
pubmed: 33406501
Medicine (Baltimore). 2021 Oct 29;100(43):e27591
pubmed: 34713835
J Natl Cancer Inst. 2015 Jan 31;107(2):
pubmed: 25638248
Biosci Rep. 2021 Aug 27;41(8):
pubmed: 34286342
BMC Cancer. 2022 Apr 7;22(1):369
pubmed: 35392854
J Clin Oncol. 2015 Dec 1;33(34):4039-47
pubmed: 26351344
Int J Mol Sci. 2020 Oct 16;21(20):
pubmed: 33081107
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Br J Cancer. 2020 Jun;122(12):1760-1768
pubmed: 32350413
Oncotarget. 2020 Mar 10;11(10):924-941
pubmed: 32206189
Ann Oncol. 2018 Dec 1;29(12):2348-2355
pubmed: 30346475
Clin Cancer Res. 2017 Jan 1;23(1):116-123
pubmed: 27993964
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140